Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHSE: 688621)
Health Care · Life Sciences Tools & Services · CN
CN¥65.59
+1.09% today · -19.7% 1Y
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHSE: 688621) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $1.06B and employs 1,335 people.
Over the last twelve months the share price has lost 19.7%, trading between 46.68 and 86.50.
Tweenvest scores Beijing Sun-Novo Pharmaceutical Research Co., Ltd. across four factors: quality 67/100, value 51/100, growth 85/100, dividend 41/100. Its strongest factor is growth.
688621 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.06B
- Revenue (TTM)
- $172.31M
- P/E
- 37.31
- EPS
- 1.76
- Dividend yield
- 0.29%
- Beta (5Y)
- -0.14
- 52-week high
- CN¥86.50
- 52-week low
- CN¥46.68
- Avg volume (3M)
- —
- Shares outstanding
- 109.28M
- Employees
- 1,335
- Next earnings
- —
About Beijing Sun-Novo Pharmaceutical Research Co., Ltd.
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. operates as a contract research organization (CRO) in China, primarily focused on the development of chemical and peptide-based pharmaceutical products. Its portfolio includes generic small-molecule chemical drugs and peptide therapies designed to treat a range of conditions such as impetigo, acne, renal anemia, hyperparathyroidism in chronic kidney disease patients on dialysis, and various pain-related ailments. Beyond drug development, the company offers a comprehensive array of research and evaluation services. These encompass testing for packaging material compatibility, detailed impurity profiling, extractables and leachables studies, and thorough safety assessments. Sun-Novo also provides support for consistency evaluations, facilitates clinical research, and delivers expert consulting and agency services for regulatory submissions. Furthermore, it conducts a full spectrum of GLP-compliant bioanalysis and pharmacokinetics-pharmacodynamics (PK/PD) studies, including pharmacokinetic, immunogenic, pharmacodynamic, and biomarker analyses. The company was founded in 2009 and is headquartered in Beijing, China.
- Founded
- 2009
- Listed since
- Jun 21, 2021
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Thermo Fisher Scientific Inc.NYSE: TMO | $232.67B | $629.27 | +0.27% |
| Danaher CorporationNYSE: DHR | $153.85B | $218.85 | +1.36% |
| WuXi AppTec Co., Ltd.SHSE: 603259 | $72.12B | CN¥162.86 | -3.00% |
| Samsung Biologics Co.,Ltd.KOSE: A207940 | $51.75B | ₩1,551,000.00 | +0.19% |
| Lonza Group AGSWX: LONN | $51.61B | CHF592.20 | +1.09% |
| Agilent Technologies, Inc.NYSE: A | $44.91B | $159.00 | +1.73% |
| IQVIA Holdings Inc.NYSE: IQV | $42.77B | $259.82 | +1.47% |
| Waters CorporationNYSE: WAT | $40.35B | $410.70 | +1.49% |
Figures last refreshed Aug 18, 2026.